Beyond Air Inc.

  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • PPHN
    • Viral Lung Infections
    • Nontuberculous Mycobacteria (NTM)
    • Solid Tumors
  • News & Events
    • Press Releases
    • Presentations
    • Publications
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar

Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect

Apr 11, 2022 7:00am EDT

Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting

Mar 08, 2022 4:35pm EST

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022

Feb 10, 2022 4:05pm EST

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

Feb 08, 2022 8:00am EST

Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors

Feb 03, 2022 4:05pm EST

Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast

Jan 27, 2022 8:00am EST

Beyond Air® Provides Regulatory Update for LungFit® PH

Dec 09, 2021 8:30am EST

Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

Dec 01, 2021 8:00am EST

Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placement

Nov 18, 2021 4:05pm EST

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022

Nov 11, 2021 4:05pm EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...17
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Important Safety Information

    †Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.

    © 2022 Beyond Air Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Search